CytomX is a biotechnology company developing the next generation of highly targeted antibody therapeutics. Our vision is to transform lives with safer, more effective therapies.
CytomX's Probody™ Platform represents a disruptive approach to discovering and developing empowered antibodies to treat areas of major unmet medical need. This novel platform is enabling the development of a diversified pipeline of empowered antibodies, including Probodies, Probody-Drug Conjugates (PDCs), bispecifics, multispecifics and other formats, addressing previously undruggable targets in cancer, inflammation and other areas of significant unmet medical need.
Through precise targeting of the disease microenvironment, Probodies have the potential to address diseases in ways that have not been possible to-date, enabling a new level of tissue targeting, selectivity and activation. CytomX has optimized its Probody Platform and established preclinical proof of concept for Probodies.
To accomplish its mission, the CytomX team embraces its corporate values of integrity, commitment, creativity, teamwork, accountability and fun.
CytomX Therapeutics Inc. was formed in 2010 from a precursor company, CytomX LLC, originally spun out of University of California, Santa Barbara in 2006. CytomX is led by a seasoned and proven management team and is well-financed by leading life science investors, including Third Rock Ventures, Canaan Partners and the Roche Venture Fund.